A Spirulina maxima-derived peptide inhibits HIV-1 infection in a human T cell line MT4
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Human immunodeficiency virus (HIV) is the causative agent of acquired immune deficiency syndrome (AIDS). Anti- HIV agents targeting various steps in HIV life cycle have been developed; however, so far, no effective drugs have been found. We show here that a peptide isolated from Spirulina maxima (SM-peptide) inhibits HIV-1 infection in a human T cell line MT4. SM-peptide inhibited HIV-1IIIB-induced cell lysis with a half-maximal inhibitory concentration (IC50) of 0.691 mM, while its 50 % cytotoxic concentration (CC50) was greater than 1.457 mM. Furthermore, the SMpeptide inhibited the HIV-1 reverse transcriptase activity and p24 antigen production. This suggests that SM-peptide is a novel candidate peptide, which may be developed as a therapeutic agent for acquired immunodeficiency syndrome patients.
Abstract
Human immunodeficiency virus (HIV) is the causative agent of acquired immune deficiency syndrome (AIDS). Anti- HIV agents targeting various steps in HIV life cycle have been developed; however, so far, no effective drugs have been found. We show here that a peptide isolated from Spirulina maxima (SM-peptide) inhibits HIV-1 infection in a human T cell line MT4. SM-peptide inhibited HIV-1IIIB-induced cell lysis with a half-maximal inhibitory concentration (IC50) of 0.691 mM, while its 50 % cytotoxic concentration (CC50) was greater than 1.457 mM. Furthermore, the SMpeptide inhibited the HIV-1 reverse transcriptase activity and p24 antigen production. This suggests that SM-peptide is a novel candidate peptide, which may be developed as a therapeutic agent for acquired immunodeficiency syndrome patients.
참고문헌 (11)
- Ay E, "Epigenetics of HIV infection : promising research areas and implications for therapy", AIDS Rev, 15, pp.181~188 (2013)
- Broder S, "The development of antiretroviral therapy and its impact on the HIV-1", AIDS pandemic, 2010, pp.85, 1~18
- Lifson MA, "Advances in biosensing strategies for HIV-1 detection, diagnosis, and therapeutic monitoring", Adv Drug Deliv Rev, 103, pp.90~104 (2016)
- Migueles SA, "Success and failure of the cellular immune response against HIV-1", Nat Immunol, 16, pp.563~570 (2015)
- Ngo DH, "Biological activities and potential health benefits of bioactive peptides derived from marine organisms", Int J Biol Macromol, 51, pp.378~383 (2012)
- Oku N, "Neamphamide A, a new HIV-inhibitory depsipeptide from the Papua New Guinea marine sponge Neamphius huxleyi", J Nat Prod, 67, pp.1407~1411 (2004)
- Plaza A, "Mirabamides A–D, depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion", J Nat Prod, 70, pp.1753~1760 (2007)
- Plaza A, "Celebesides A–C and theopapuamides B–D, depsipeptides from an Indonesian sponge that inhibit HIV-1 entry", J Org Chem, 74, pp.504~512 (2009)
- Vo TS, "Potential anti-HIV agents from marine resources : an overview", Mar Drugs, 8, pp.2871~2892 (2010)
- Vo TS, "The role of peptides derived from Spirulina maxima in downregulation of FcepsilonRI-mediated allergic responses", Mol Nutr Food Res, 58, pp.2226~2234 (2014)
- Zampella A, "Homophymine A, an anti-HIV cyclodepsipeptide from the sponge Homophymia sp", J Org Chem, 73, pp.5319~5327 (2008)